

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 October 2022 (06.10.2022)



(10) International Publication Number
WO 2022/207921 A1

- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61K 39/00* (2006.01)
- (21) **International Application Number:**
PCT/EP2022/058788
- (22) **International Filing Date:**
01 April 2022 (01.04.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
21166756.3 01 April 2021 (01.04.2021) EP
- (71) **Applicant:** JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG [DE/DE]; Sandering 2, 97070 Würzburg (DE).
- (72) **Inventors:** WAJANT, Harald; Spitzwiese 7a, 97270 Kist (DE). BEILHACK, Andreas; Judenbühlweg 38A, 97082 Würzburg (DE). MEDLER, Juliane; Niesiger Str. 119a, 36039 Fulda (DE). STEINFATT, Tim; Rottendorfer
- Straße 33, 97074 Würzburg (DE). ROMPAEY, Luc VAN; Bloemenbosdreef 4, 3140 Keerbergen (BE).
- (74) **Agent:** J A KEMP LLP; 80 Turnmill Street, London, Greater London EC1M 5QU (GB).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) **Title:** NOVEL TNFR2 BINDING MOLECULES




FIGURE 1

(57) **Abstract:** The present disclosure provides a binding molecule that specifically binds TNFR2, but not TNFR1. Preferably the binding molecule is an FcγR-independent agonist of TNFR2 and more preferably has a valency of at least two for binding TNFR2. The binding molecules have a variety of uses including diagnostic and therapeutic. The ability of the binding molecules to be able to modulate immune responses means that they are particularly suited for treating autoimmune diseases, or inflammatory conditions.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))